Prevention of chronic kidney disease and its consequences:The role of socioeconomic status by Vart, Priya
  
 University of Groningen
Prevention of chronic kidney disease and its consequences
Vart, Priya
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Vart, P. (2015). Prevention of chronic kidney disease and its consequences: The role of socioeconomic
status. [Groningen]: University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
6
CONSEQUENCES OF THE USE OF
THE ALBUMIN TO CREATININE RATIO
INSTEAD OF 24-HOUR URINARY ALBUMIN
EXCRETION FOR ALBUMINURIA STAGING
Priya Vart
Lineke Scheven
Hiddo J Lambers Heerspink














New	  guidelines	  advocate	  the	  use	  of	  albumin	  to	  creatinine	  ratio	  (ACR)	  in	  a	  urine	  sample	  instead	  of	  
24h-­‐urinary	  albumin	  excretion	   (24hr-­‐UAE)	   for	   staging	  albuminuria.	  Concern	  has	  been	  expressed	  
that	   this	  may	   result	   in	  misclassification	   because	   of	   among	   others	   interindividual	   differences	   in	  
urinary	   creatinine	   excretion.	   We	   examined	   7,623	   participants	   of	   the	   PREVEND	   and	   RENAAL	  
studies	   reclassification	   when	   using	   ACR	   instead	   of	   24hr-­‐UAE,	   the	   characteristics	   of	   reclassified	  
participants	  and	  their	  outcome.	  Albuminuria	  was	  categorized	  into	  3	  categories:	  <30,	  30-­‐300,	  >300	  
mg/24h	   and	   mg/g.	   When	   using	   ACR	   in	   the	   early	   morning	   void	   instead	   of	   24hr-­‐UAE	   88%	   of	  
participants	   were	   classified	   in	   corresponding	   albuminuria	   categories.	   307	   (4.0%)	   participants	  
were	  classified	  to	  a	  higher	  and	  603	  (7.9%)	  to	  a	  lower	  category.	  Participants	  that	  were	  reclassified	  
upward	   had	   in	   general	   a	   worse	   cardiovascular	   risk	   profile	   when	   compared	   to	   non-­‐reclassified	  
participants,	   whereas	   the	   reverse	   was	   true	   for	   downward	   reclassified	   participants.	   In	   line,	   Cox	  
regression	   analyses	   showed	   that	   upward	   reclassification	   when	   using	   early	   morning	   void	   ACR	  
instead	   of	   24hr-­‐UAE	   was	   associated	   with	   a	   tendency	   for	   increased	   risk	   for	   cardiovascular	  
morbidity	   and	   mortality	   and	   and	   all-­‐cause	   mortality,	   whereas	   downward	   reclassification	   was	  
associated	  with	  a	  tendency	  for	  lower	  risk.	  The	  Net	  Reclassification	  index,	  adjusted	  for	  age,	  gender	  
and	  duration	  of	  follow-­‐up,	  was	  0.107	  (p=0.002)	  for	  cardiovascular	  events	  and	  0.089	  (p<0.001)	  for	  
all-­‐cause	  mortality.	  Our	   results	   indicate	   that	   although	   there	   is	   reclassification	  when	  using	   early	  
morning	   void	   ACR	   instead	   of	   24hr-­‐UAE,	   reclassification	   is	   limited	   and	   in	   general	   indicative	   for	  
presence	  of	  cardiovascular	  (CV)	  risk	  factors	  and	  prognosis.	  




Elevated	  albuminuria	  has	  been	  established	  as	  a	  valuable	  risk	  marker	  for	  renal	  and	  cardiovascular	  
complications	  (1-­‐5).	  Albuminuria	  can	  be	  assessed	  in	  several	  ways,	  of	  which	  measurement	  of	  24-­‐
hour	   urinary	   albumin	   excretion	   (24hr-­‐UAE)	  was	   for	   long	   considered	   the	   gold	   standard.	   Recent	  
guidelines,	   however,	   advocate	   the	  use	  of	   the	   albumin	   to	   creatinine	   ratio	   (ACR)	   in	   a	   spot	   urine	  
sample	  (6).	  Opponents	  of	  the	  use	  of	  ACR	  to	  assess	  albuminuria	  argue	  that	  sometimes	  a	  subject	  is	  
called	  having	   increased	  albuminuria	  based	  on	  an	  ACR,	  whereas	  a	  24h-­‐urine	  collection	  does	  not	  
support	  this.	  
Reasons	  for	  discrepancy	  between	  albuminuria	  staging	  based	  on	  24hr-­‐UAE	  versus	  ACR	  can	  be,	  
first,	   that	   an	   increased	   ACR	  may	   not	   only	   be	   due	   to	   an	   increase	   in	   albuminuria,	   but	   also	   to	   a	  
decrease	  in	  urinary	  creatinine	  concentration.	  Creatinine,	  as	  waste	  product	  of	  muscle	  catabolism,	  
is	   dependent	   on	   muscle	   mass	   and	   consequently	   differs	   by,	   among	   others,	   age	   and	   gender.	  
Second,	   albuminuria	   is	   subject	   to	   a	   circadian	   rhythm,	   whereas	   urinary	   creatinine	   excretion	   is	  
fairly	   stable	   during	   the	   day	   (7).	   Assessment	   of	   the	   ACR	  in	   a	   first	   morning	   urine	   sample	   may	  
therefore	  reveal	  another	  value	  than	  the	  ACR	  in	  a	  24h-­‐urine	  collection.	  Third,	  24hr-­‐UAE	  is	  subject	  
to	   collection	   errors	  and	   reclassification	   to	   another	   risk	   category	   based	   on	   spot	   urine	   ACR	  may	  
therefore	  also	  be	  due	  to	  incorrect	  24h	  urine	  collection.	  	  
The	  aim	  of	  this	  study	  is	  to	  analyze	  whether	  misclassification	  by	  expressing	  albuminuria	  as	  ACR	  
instead	   of	   24hr-­‐UAE	   plays	   an	   important	   role.	   Importance	   is	   assessed	   by	  calculating	  the	  
percentage	   of	   participants	   in	   which	   it	   occurs,	  as	   well	   as	   by	   studying	   whether	   reclassification	  
reflects	   clinical	   characteristics	   and	   prognosis	   in	   these	   participants.	   For	   these	   analyses	  we	   used	  
data	   of	  two	   studies	   in	   which	   sera,	  and	   24h-­‐urine	   and	   first	   morning	  urine	   samples	   were	  
available	  and	  allowed	  calculation	  of	  24hr-­‐UAE	  and	  ACR.	  
METHODS	  	  
This	   study	   is	   collaboration	   between	   the	   investigators	   of	   the	   Prevention	   of	   REnal	   and	   Vascular	  
ENd-­‐stage	  Disease	   (PREVEND)	   study	   and	   the	   Reduction	   of	   Endpoints	   in	  Non-­‐insulin	   dependent	  
diabetes	  mellitus	  with	  the	  Angiotensin	  II	  Antagonist	  Losartan	  (RENAAL)	  study.	  This	  collaboration	  
was	  established	   to	  ensure	   sufficient	  participants	   in	  all	   three	  albuminuria	   classes	  of	   the	  present	  
CKD	  staging	  system	  for	  analyses.	  
Study	  design	  and	  population	  
The	   PREVEND	   study	   is	   a	   prospective	   cohort	   study	   which	   investigates	   the	   natural	   course	   of	  
albuminuria	   and	   its	   relation	   to	   renal	   and	   cardiovascular	   disease.	   Details	   of	   the	   study	   protocol	  
have	  been	  published	  elsewhere	  (8,	  9).	  In	  brief,	  the	  participants	  of	  the	  PREVEND	  study	  have	  been	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selected	   in	   1997	   from	   subjects	   of	   the	   general	   population	   in	   Groningen,	   aged	   28-­‐75	   years.	  
Pregnancy	  and	   insulin	  usage	  were	  exclusion	  criteria.	   In	   total,	  8,592	   subjects	  participated	   in	   the	  
first	   screening	   (1997-­‐98),	  of	  which	  6,000	  participants	  had	  a	  UAC	  ≥10	  mg/L	   in	   the	  spot	  morning	  
urine	  sample	  and	  2,592	  participants	  a	  UAC	  <10	  mg/L.	  This	  screening	  consisted	  of	  two	  outpatient	  
clinic	   visits,	   where	   baseline	   measurements	   were	   performed.	   Part	   of	   this	   screening	   was	   that	  
participants	   collected	   two	   24h	   urines,	   of	   which	   the	   first	   sample	   was	   used	   for	   the	   present	  
analyses.	  
The	  RENAAL	  study	  is	  a	  multinational,	  double-­‐blind	  randomised	  placebo-­‐controlled	  study	  that	  
evaluated	  the	  renal	  protective	  effects	  of	  the	  angiotensin-­‐II	  blocker	  losartan	  in	  patients	  with	  type	  
2	  diabetes	  and	  nephropathy.	  The	  study	  design	  and	  results	  have	  been	  reported	  elsewhere	  (10-­‐12).	  
In	  brief,	   in-­‐	  and	  exclusion	  criteria	   for	   the	  RENAAL	  study	  were:	   type	  2	  diabetes	   (assessed	  as	  age	  
over	  30	  years	  old	  at	   time	  of	  diagnosis,	  no	  history	  of	  ketoacidosis	  and	  not	  using	   insulin	   therapy	  
within	  6	  months	  after	  diagnosis),	  a	  serum	  creatinine	  between	  1.3	  and	  3.0	  mg/dl	  (1.5	  to	  3.0	  mg/dl	  
for	  males	  more	  than	  60	  kg),	  a	  urinary	  ACR	  from	  a	  first-­‐morning	  specimen	  of	  at	   least	  300	  mg/g,	  
HbA1c<12%	  and	  age	  between	  31	  and	  70	  years.	  All	  patients	  collected	  at	  baseline	  a	  first-­‐morning	  
void	  urine	  sample	   for	  albumin	  and	  creatinine	  assessment.	   In	  addition,	  a	   random	  sample	  of	  701	  
patients	  collected	  24-­‐hour	  urine	  samples	  for	  quantification	  of	  UAE.	  	  
Both	  studies	  were	  approved	  by	  medical	  ethics	  committees	  and	  conducted	  in	  accordance	  with	  
the	   International	  Conference	  of	  Harmonization	  Good	  Clinical	  Practice	  Guidelines	  and	  adhere	   to	  
the	  ethical	  principles	  that	  have	  their	  origin	  in	  the	  Declaration	  of	  Helsinki.	  
For	   the	  present	  analyses	  we	  use	  data	  of	  participants	   (N=7,623)	   in	   the	   two	  studies	  of	  whom	  
24h-­‐urines	  and	  early	  morning	  urine	  samples	  were	  available	  and	  allowed	  calculation	  of	  24hr-­‐UAE	  
and	   ACR	   in	   an	   early	   morning	   sample	   (6,922	   of	   8,592	   PREVEND	   participants	   and	   701	   of	   1,513	  
RENAAL	   participants).	   There	   were	   too	   few	   participants	   in	   the	   PREVEND	   study	   with	   severely	  
increased	  albuminuria	  (i.e.	  >300	  mg/g	  or	  >300	  mg/24-­‐hr)	  and	  too	  few	  participants	  in	  the	  RENAAL	  
study	  with	  normal	  to	  mildly	  increased	  albuminuria	  (<30mg/g	  or	  <30	  mg/24-­‐hr)	  to	  allow	  separate	  
analysis	  of	   the	  effect	  of	   reclassification	  when	  using	  an	  early	  morning	  void	  ACR	   instead	  of	  24hr-­‐
UAE	  according	   to	   the	  KDIGO	  albuminuria	   stages.	  To	  our	  knowledge,	  PREVEND	  and	  RENAAL	  are	  
the	  only	  studies	  that	  have	  both	  measures	  of	  albuminuria	   i.e.	  early	  morning	  void	  ACR	  and	  24hr-­‐
UAE.	  Therefore,	  we	  combined	  the	  PREVEND	  and	  RENAAL	  studies	  to	  study	  with	  sufficient	  power	  
the	   effect	   of	   reclassification	   when	   using	   early	  morning	   void	   ACR	   instead	   of	   24hr	   UAE	   defined	  
albuminuria	  categories.	  
Measurements	  and	  Definitions	  
At	   the	   baseline	   visit	   anthropometrical	   measurements	   were	   performed,	   blood	   pressure	   was	  
measured	   and	   fasting	   blood	   and	   urine	   samples	   were	   taken	   in	   which	   analytes	   were	  measured	  
using	   routine	   methodologies.	   Urinary	   albumin	   concentration	   was	   measured	   by	   nephelometry	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(PREVEND:	   BNII,	   Dade	   Behring	   Diagnostic,	   Marburg,	   Germany;	   RENAAL:	   Beckman	   Array,	  
Beckman,	  Fullerton,	  California,	  USA).	  	  
Participants	  that	  smoked	  in	  the	  year	  prior	  to	  the	  baseline	  screening	  were	  regarded	  smokers.	  
Cardiovascular	   disease	   history	   was	   defined	   by	   self-­‐report.	   Hypertension	   was	   defined	   in	  
accordance	  with	   the	   JNC-­‐7	   criteria	   as	   systolic	   blood	   pressure	   (SBP)	   of	   ≥140	  mmHg	   or	   diastolic	  
blood	  pressure	  (DBP)	  ≥90	  mmHg	  or	  use	  of	  antihypertensive	  medication.	  Diabetes	  was	  defined	  in	  
accordance	   with	   the	   American	   Diabetes	   Association	   criteria	   as	   a	   fasting	   glucose	   level	   of	   >7.0	  
mmol/L	   or	   non-­‐fasting	   glucose	   level	   of	   >11.1	  mmol/L	   or	   use	   of	   anti-­‐diabetic	  medication.	   Body	  
mass	   index	   (BMI)	   was	   calculated	   as	   the	   ratio	   between	   weight	   and	   the	   square	   of	   height	  
(weight/height2).	  Errors	  in	  24h-­‐urine	  collections	  were	  defined	  as	  the	  upper	  and	  lower	  2.5%	  of	  the	  
difference	  between	  the	  estimated	  creatinine	  excretion	  rate	  and	  the	  actually	  measured	  creatinine	  
excretion	   rate.	   The	   estimated	   creatinine	   excretion	   rate	   was	   calculated	   by:	   879.89	   +	   12.51	   *	  
weight	  (kg)	  -­‐	  6.19	  *	  age	  +	  (34.51	  if	  black)	  -­‐	  (379.42	  if	  female)	  (14).	  
Albuminuria	  measures	  
24hr-­‐UAE	   (mg/24h)	   is	   given	   as	   urinary	   albumin	   concentration	   times	   volume	   of	   one	   24h-­‐urine	  
collection.	  ACR	  (mg/g)	  was	  calculated	  by	  dividing	  urinary	  albumin	  concentration	  (mg/L)	  by	  urinary	  
creatinine	  concentration	  (g/L).	  Cut-­‐off	  values	   indicating	  normoalbuminuria,	  and	  moderately	  and	  
severely	  increased	  albuminuria	  were	  defined	  in	  accordance	  with	  the	  prevailing	  guideline	  (6):	  for	  
24h	  UAE	  <30,	  30-­‐300	  and	  >300	  mg/24h,	  and	  for	  ACR	  <30,	  30-­‐300	  and	  >300	  mg/g,	  respectively.	  	  
Outcome	  	  
The	   outcomes	   assessed	   were	   cardiovascular	   morbidity	   and	   mortality	   and	   all-­‐cause	   mortality	  
during	   follow-­‐up.	   In	  PREVEND	   information	  on	  date	  and	  cause	  of	  death	  was	  obtained	  by	   record	  
linkage	   with	   the	   Dutch	   Central	   Bureau	   of	   Statistics.	   Information	   on	   hospitalization	   for	  
cardiovascular	  morbidity	  was	  obtained	   from	  PRISMANT,	   the	  Dutch	  national	   registry	  of	   hospital	  
discharge	   diagnoses.	   In	   RENAAL	   information	   on	   cardiovascular	   morbidity	   and	   mortality	   was	  
collected	  prospectively.	  For	   this	   study,	   incident	  cardiovascular	  morbidity	  was	  defined	  according	  
the	  Major	  Adverse	  Cardiovascular	  Events	  (MACE)	  criteria	  (11).	  	  
Statistical	  analysis	  	  
Baseline	  characteristics	  were	  calculated	  for	  the	  overall	  population	  and	  for	  participants	  stratified	  
according	   to	   the	   three	   UAE	   categories.	   Continuous	   data	   are	   reported	   as	   mean	   ±	   standard	  
deviation.	   In	   case	   of	   non-­‐parametric	   data	   distribution,	   medians	   with	   interquartile	   ranges	   are	  
presented.	   Differences	   in	   baseline	   characteristics	   between	   the	   three	   UAE	   subgroups	   were	  







selected	   in	   1997	   from	   subjects	   of	   the	   general	   population	   in	   Groningen,	   aged	   28-­‐75	   years.	  
Pregnancy	  and	   insulin	  usage	  were	  exclusion	  criteria.	   In	   total,	  8,592	   subjects	  participated	   in	   the	  
first	   screening	   (1997-­‐98),	  of	  which	  6,000	  participants	  had	  a	  UAC	  ≥10	  mg/L	   in	   the	  spot	  morning	  
urine	  sample	  and	  2,592	  participants	  a	  UAC	  <10	  mg/L.	  This	  screening	  consisted	  of	  two	  outpatient	  
clinic	   visits,	   where	   baseline	   measurements	   were	   performed.	   Part	   of	   this	   screening	   was	   that	  
participants	   collected	   two	   24h	   urines,	   of	   which	   the	   first	   sample	   was	   used	   for	   the	   present	  
analyses.	  
The	  RENAAL	  study	  is	  a	  multinational,	  double-­‐blind	  randomised	  placebo-­‐controlled	  study	  that	  
evaluated	  the	  renal	  protective	  effects	  of	  the	  angiotensin-­‐II	  blocker	  losartan	  in	  patients	  with	  type	  
2	  diabetes	  and	  nephropathy.	  The	  study	  design	  and	  results	  have	  been	  reported	  elsewhere	  (10-­‐12).	  
In	  brief,	   in-­‐	  and	  exclusion	  criteria	   for	   the	  RENAAL	  study	  were:	   type	  2	  diabetes	   (assessed	  as	  age	  
over	  30	  years	  old	  at	   time	  of	  diagnosis,	  no	  history	  of	  ketoacidosis	  and	  not	  using	   insulin	   therapy	  
within	  6	  months	  after	  diagnosis),	  a	  serum	  creatinine	  between	  1.3	  and	  3.0	  mg/dl	  (1.5	  to	  3.0	  mg/dl	  
for	  males	  more	  than	  60	  kg),	  a	  urinary	  ACR	  from	  a	  first-­‐morning	  specimen	  of	  at	   least	  300	  mg/g,	  
HbA1c<12%	  and	  age	  between	  31	  and	  70	  years.	  All	  patients	  collected	  at	  baseline	  a	  first-­‐morning	  
void	  urine	  sample	   for	  albumin	  and	  creatinine	  assessment.	   In	  addition,	  a	   random	  sample	  of	  701	  
patients	  collected	  24-­‐hour	  urine	  samples	  for	  quantification	  of	  UAE.	  	  
Both	  studies	  were	  approved	  by	  medical	  ethics	  committees	  and	  conducted	  in	  accordance	  with	  
the	   International	  Conference	  of	  Harmonization	  Good	  Clinical	  Practice	  Guidelines	  and	  adhere	   to	  
the	  ethical	  principles	  that	  have	  their	  origin	  in	  the	  Declaration	  of	  Helsinki.	  
For	   the	  present	  analyses	  we	  use	  data	  of	  participants	   (N=7,623)	   in	   the	   two	  studies	  of	  whom	  
24h-­‐urines	  and	  early	  morning	  urine	  samples	  were	  available	  and	  allowed	  calculation	  of	  24hr-­‐UAE	  
and	   ACR	   in	   an	   early	   morning	   sample	   (6,922	   of	   8,592	   PREVEND	   participants	   and	   701	   of	   1,513	  
RENAAL	   participants).	   There	   were	   too	   few	   participants	   in	   the	   PREVEND	   study	   with	   severely	  
increased	  albuminuria	  (i.e.	  >300	  mg/g	  or	  >300	  mg/24-­‐hr)	  and	  too	  few	  participants	  in	  the	  RENAAL	  
study	  with	  normal	  to	  mildly	  increased	  albuminuria	  (<30mg/g	  or	  <30	  mg/24-­‐hr)	  to	  allow	  separate	  
analysis	  of	   the	  effect	  of	   reclassification	  when	  using	  an	  early	  morning	  void	  ACR	   instead	  of	  24hr-­‐
UAE	  according	   to	   the	  KDIGO	  albuminuria	   stages.	  To	  our	  knowledge,	  PREVEND	  and	  RENAAL	  are	  
the	  only	  studies	  that	  have	  both	  measures	  of	  albuminuria	   i.e.	  early	  morning	  void	  ACR	  and	  24hr-­‐
UAE.	  Therefore,	  we	  combined	  the	  PREVEND	  and	  RENAAL	  studies	  to	  study	  with	  sufficient	  power	  
the	   effect	   of	   reclassification	   when	   using	   early	  morning	   void	   ACR	   instead	   of	   24hr	   UAE	   defined	  
albuminuria	  categories.	  
Measurements	  and	  Definitions	  
At	   the	   baseline	   visit	   anthropometrical	   measurements	   were	   performed,	   blood	   pressure	   was	  
measured	   and	   fasting	   blood	   and	   urine	   samples	   were	   taken	   in	   which	   analytes	   were	  measured	  
using	   routine	   methodologies.	   Urinary	   albumin	   concentration	   was	   measured	   by	   nephelometry	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(PREVEND:	   BNII,	   Dade	   Behring	   Diagnostic,	   Marburg,	   Germany;	   RENAAL:	   Beckman	   Array,	  
Beckman,	  Fullerton,	  California,	  USA).	  	  
Participants	  that	  smoked	  in	  the	  year	  prior	  to	  the	  baseline	  screening	  were	  regarded	  smokers.	  
Cardiovascular	   disease	   history	   was	   defined	   by	   self-­‐report.	   Hypertension	   was	   defined	   in	  
accordance	  with	   the	   JNC-­‐7	   criteria	   as	   systolic	   blood	   pressure	   (SBP)	   of	   ≥140	  mmHg	   or	   diastolic	  
blood	  pressure	  (DBP)	  ≥90	  mmHg	  or	  use	  of	  antihypertensive	  medication.	  Diabetes	  was	  defined	  in	  
accordance	   with	   the	   American	   Diabetes	   Association	   criteria	   as	   a	   fasting	   glucose	   level	   of	   >7.0	  
mmol/L	   or	   non-­‐fasting	   glucose	   level	   of	   >11.1	  mmol/L	   or	   use	   of	   anti-­‐diabetic	  medication.	   Body	  
mass	   index	   (BMI)	   was	   calculated	   as	   the	   ratio	   between	   weight	   and	   the	   square	   of	   height	  
(weight/height2).	  Errors	  in	  24h-­‐urine	  collections	  were	  defined	  as	  the	  upper	  and	  lower	  2.5%	  of	  the	  
difference	  between	  the	  estimated	  creatinine	  excretion	  rate	  and	  the	  actually	  measured	  creatinine	  
excretion	   rate.	   The	   estimated	   creatinine	   excretion	   rate	   was	   calculated	   by:	   879.89	   +	   12.51	   *	  
weight	  (kg)	  -­‐	  6.19	  *	  age	  +	  (34.51	  if	  black)	  -­‐	  (379.42	  if	  female)	  (14).	  
Albuminuria	  measures	  
24hr-­‐UAE	   (mg/24h)	   is	   given	   as	   urinary	   albumin	   concentration	   times	   volume	   of	   one	   24h-­‐urine	  
collection.	  ACR	  (mg/g)	  was	  calculated	  by	  dividing	  urinary	  albumin	  concentration	  (mg/L)	  by	  urinary	  
creatinine	  concentration	  (g/L).	  Cut-­‐off	  values	   indicating	  normoalbuminuria,	  and	  moderately	  and	  
severely	  increased	  albuminuria	  were	  defined	  in	  accordance	  with	  the	  prevailing	  guideline	  (6):	  for	  
24h	  UAE	  <30,	  30-­‐300	  and	  >300	  mg/24h,	  and	  for	  ACR	  <30,	  30-­‐300	  and	  >300	  mg/g,	  respectively.	  	  
Outcome	  	  
The	   outcomes	   assessed	   were	   cardiovascular	   morbidity	   and	   mortality	   and	   all-­‐cause	   mortality	  
during	   follow-­‐up.	   In	  PREVEND	   information	  on	  date	  and	  cause	  of	  death	  was	  obtained	  by	   record	  
linkage	   with	   the	   Dutch	   Central	   Bureau	   of	   Statistics.	   Information	   on	   hospitalization	   for	  
cardiovascular	  morbidity	  was	  obtained	   from	  PRISMANT,	   the	  Dutch	  national	   registry	  of	   hospital	  
discharge	   diagnoses.	   In	   RENAAL	   information	   on	   cardiovascular	   morbidity	   and	   mortality	   was	  
collected	  prospectively.	  For	   this	   study,	   incident	  cardiovascular	  morbidity	  was	  defined	  according	  
the	  Major	  Adverse	  Cardiovascular	  Events	  (MACE)	  criteria	  (11).	  	  
Statistical	  analysis	  	  
Baseline	  characteristics	  were	  calculated	  for	  the	  overall	  population	  and	  for	  participants	  stratified	  
according	   to	   the	   three	   UAE	   categories.	   Continuous	   data	   are	   reported	   as	   mean	   ±	   standard	  
deviation.	   In	   case	   of	   non-­‐parametric	   data	   distribution,	   medians	   with	   interquartile	   ranges	   are	  





calculated	  with	   a	   Chi-­‐square	   test	   for	   categorical	   data	   and	   for	   continuous	   data	  with	   a	   one-­‐way	  
ANOVA	  (in	  case	  of	  non-­‐parametric	  data	  a	  Kruskal–Wallis	  ANOVA	  by	  ranks	  test).	  	  
To	  assess	  reclassification,	  we	  created	  3	  x	  3	  cross-­‐tabulations	  using	  the	  aforementioned	  clinically	  
relevant	   cut-­‐off	   values	   for	   24h	   UAE	   and	   ACR.	   In	   these	   tables	   the	   proportion	   of	   reclassified	  
participants	  was	  calculated.	  The	  McNemar	  test,	  a	  nonparametric	  test	  for	  comparing	  two	  related	  
samples,	  was	  used	   to	   test	   the	   significance	  of	   the	   ratios	  of	  up	  and	  down	  classification	  between	  
24h	   UAE	   versus	   ACR.	   Differences	   in	   characteristics	   between	   non-­‐reclassified	   and	   reclassified	  
participants	   in	   table	   2	   were	   calculated	   with	   a	   Chi-­‐square	   test	   for	   categorical	   data,	   and	   for	  
continuous	  data	  with	  Student’s	  t-­‐test	  (in	  case	  of	  normally	  distributed	  data)	  or	  Mann	  Whitney	  test	  
(in	  case	  of	  non-­‐parametric	  data).	  
In	  addition,	  we	  assessed	  whether	  risk	  of	  cardiovascular	  morbidity	  and	  mortality,	  and	  all-­‐cause	  
mortality	   differed	   between	   participants	   reclassified	   and	   those	   not	   reclassified.	   For	   risk	  
assessment	  Cox	  regression	  analyses	  were	  used,	  first	  crude,	  second	  adjusted	  for	  age	  and	  gender,	  
and	  subsequently	  also	   for	  baseline	  UAE	  and	  strata	   for	  participation	   in	   the	  PREVEND	  or	  RENAAL	  
study.	   Follow-­‐up	   time	   was	   defined	   as	   the	   period	   to	   the	   first	   outcome	   or	   loss	   to	   follow-­‐up.	  
Individuals	  who	  were	  free	  of	  these	  outcomes	  by	  December	  31,	  2000	  in	  the	  RENAAL	  study	  and	  by	  
January	   1,	   2009	   in	   the	   PREVEND	   study,	   were	   subject	   to	   administrative	   censoring.	   To	   assess	  
reclassification	  we	  calculated	  net	  reclassification	  improvement	  (NRI)	  for	  cardiovascular	  morbidity	  
and	  mortality	  and	  all-­‐cause	  mortality	  (13).	  Given	  the	  difference	  in	  follow-­‐up	  duration	  in	  PREVEND	  
and	  RENAAL,	  we	  calculated	  NRI	  adjusted	  for	  age,	  gender	  as	  well	  as	  for	  duration	  of	  follow-­‐up.	  	  
We	  confirmed	  our	  results	  in	  sensitivity	  analyses.	  First,	  to	  assess	  the	  accuracy	  of	  the	  data,	  an	  
estimated	   UAE	   was	   calculated	   for	   the	   combined	   study	   population	   and	   for	   individual	   studies	  
(calculated	  by	  multiplying	  ACR	  by	  estimated	  creatinine	  excretion	   rate),	   and	   compared	  with	   the	  
actually	   measured	   UAE	   data	   (14).	   Second,	   to	   account	   for	   error	   in	   24-­‐hr	   urine	   collection,	   we	  
excluded	   participants	   with	   possible	   error	   in	   their	   24-­‐hr	   urine	   collection.	   Errors	   in	   24-­‐hr	   urine	  
collection	  were	  assessed	  by	  comparing	  measured	  and	  expected	  24-­‐hr	  urine	  creatinine	  excretion.	  
Participants	   with	   measured	   24hr	   urinary	   creatinine	   excretion	   containing	   less	   than	   50%	   of	   the	  
estimated	   24-­‐hr	   urine	   creatinine	   excretion	   were	   excluded.	   The	   estimated	   creatinine	   excretion	  
rate	  was	  calculated	  according	  to	  literature	  by:	  eCER	  =	  879.89	  +	  12.51	  *	  weight	  (kg)	  -­‐	  6.19	  *	  age	  +	  
(34.51	  if	  black)	  -­‐	  (379.42	  if	  female)	  (15).	  Third,	  given	  the	  difference	  in	  the	  baseline	  characteristics	  
of	  PREVEND	  and	  RENAAL	  study	  participants,	  combining	  cohorts	  might	  confound	  our	  analyses.	  We	  
therefore	   examined	   the	   PREVEND	   and	   RENAAL	   studies	   also	   separately.	   To	   allow	   sufficient	  
numbers	   of	   participants	   in	   three	   albuminuria	   categories,	   in	   both	   PREVEND	   and	   RENAAL,	  
albuminuria	  had	  to	  be	  categorized	  into	  <15,	  15-­‐30	  and	  >30	  (mg/g	  or	  mg/24hr)	  for	  the	  PREVEND	  
study,	  and	  into	  <300,	  300-­‐1500	  and	  >1500	  (mg/g	  or	  mg/24hr)	  for	  the	  RENAAL	  study.	  
All	   calculations	  were	   performed	  with	   STATA	   (version	   12.0)	   software.	   A	   p-­‐value	   of	   less	   than	  





Table	  1	  shows	  the	  baseline	  characteristics	  of	  the	  7,623	  participants.	  Mean	  age	  of	  the	  total	  cohort	  
was	  50.5	  ±	  12.7	  years	  and	  half	  of	  the	  participants	  were	  female.	  When	  albuminuria	  was	  assessed	  
as	  24hr-­‐UAE	  (mg/24h)	  or	  as	  ACR	  (mg/g),	  the	  prevalence	  of	  moderately	  increased	  albuminuria	  was	  
13.5%	  and	  11.5%,	   respectively,	  and	   the	  prevalence	  of	   severely	   increased	  albuminuria	  9.7%	  and	  
8.8%,	   respectively.	   Table	   1	   also	   shows	   that	   when	   participants	   had	   higher	   24hr-­‐UAE	   their	  
cardiovascular	   risk	  profile	  was	  higher,	   i.e.	   these	  participants	  were	  older,	  more	  often	  male,	   had	  
higher	  BMI	  and	  a	  higher	  prevalence	  of	  hypertension	  and	  diabetes.	  
Reclassification	  when	  using	  ACR	  instead	  of	  24hr-­‐UAE	  
When	   using	   ACR	   instead	   of	   24hr-­‐UAE	   88%	   of	   participants	   were	   classified	   in	   corresponding	  
albuminuria	   categories	   (Table	   2).	   307	   (4.0%)	   participants	   were	   classified	   to	   a	   higher	   and	   603	  
(7.9%)	   to	   a	   lower	   category	   (Table	   2).	   Participants	   who	   were	   reclassified	   upward	   to	   a	   higher	  
albuminuria	  category	  when	  using	  ACR	   instead	  of	  24hr-­‐UAE	  (for	  example	  when	  comparing	  24hr-­‐
UAE	  30-­‐300	  mg/24h	  and	  reclassification	  to	  a	  higher	  ACR	  category)	  were	  older	   in	  comparison	  to	  
participants	  that	  were	  not	  reclassified	  (63.8	  ±	  7.4	  vs.	  59.1	  ±	  11.2	  yrs,	  p<0.001),	  and	  more	  often	  of	  
female	   gender	   (64.7	   vs.	   38.3	   %,	   p<0.001),	   diabetic	   (73.5	   vs	   19.5,	   p<0.001)	   and	   hypertensive	  
(97.1%	  vs	  70.0%,	  p<0.001).	  Furthermore,	  they	  had	  a	  higher	  body	  mass	  index	  (29.2	  vs.	  28.2	  kg/m2,	  
p<0.001),	   and	  more	   often	   had	   a	   cardiovascular	   disease	   history	   (42.5%	   vs.	   15.1%,	   p<0.001).	   In	  
contrast,	  the	  participants	  reclassified	  downward	  to	  a	  lower	  albuminuria	  stage	  were	  less	  often	  of	  
female	   gender	   (33.1%	   vs.	   38.3%,	   p=0.07),	   diabetic	   (9.3%	   vs.	   19.5%,	   p<0.001)	   and	   hypertensive	  
(57.4%	   vs.	   70.0%,	   p<0.001).	   Furthermore,	   they	   had	   less	   often	   a	   cardiovascular	   disease	   history	  
(11.3%	  vs.	  15.1%	  p<0.001)	  (Table	  2).	  







calculated	  with	   a	   Chi-­‐square	   test	   for	   categorical	   data	   and	   for	   continuous	   data	  with	   a	   one-­‐way	  
ANOVA	  (in	  case	  of	  non-­‐parametric	  data	  a	  Kruskal–Wallis	  ANOVA	  by	  ranks	  test).	  	  
To	  assess	  reclassification,	  we	  created	  3	  x	  3	  cross-­‐tabulations	  using	  the	  aforementioned	  clinically	  
relevant	   cut-­‐off	   values	   for	   24h	   UAE	   and	   ACR.	   In	   these	   tables	   the	   proportion	   of	   reclassified	  
participants	  was	  calculated.	  The	  McNemar	  test,	  a	  nonparametric	  test	  for	  comparing	  two	  related	  
samples,	  was	  used	   to	   test	   the	   significance	  of	   the	   ratios	  of	  up	  and	  down	  classification	  between	  
24h	   UAE	   versus	   ACR.	   Differences	   in	   characteristics	   between	   non-­‐reclassified	   and	   reclassified	  
participants	   in	   table	   2	   were	   calculated	   with	   a	   Chi-­‐square	   test	   for	   categorical	   data,	   and	   for	  
continuous	  data	  with	  Student’s	  t-­‐test	  (in	  case	  of	  normally	  distributed	  data)	  or	  Mann	  Whitney	  test	  
(in	  case	  of	  non-­‐parametric	  data).	  
In	  addition,	  we	  assessed	  whether	  risk	  of	  cardiovascular	  morbidity	  and	  mortality,	  and	  all-­‐cause	  
mortality	   differed	   between	   participants	   reclassified	   and	   those	   not	   reclassified.	   For	   risk	  
assessment	  Cox	  regression	  analyses	  were	  used,	  first	  crude,	  second	  adjusted	  for	  age	  and	  gender,	  
and	  subsequently	  also	   for	  baseline	  UAE	  and	  strata	   for	  participation	   in	   the	  PREVEND	  or	  RENAAL	  
study.	   Follow-­‐up	   time	   was	   defined	   as	   the	   period	   to	   the	   first	   outcome	   or	   loss	   to	   follow-­‐up.	  
Individuals	  who	  were	  free	  of	  these	  outcomes	  by	  December	  31,	  2000	  in	  the	  RENAAL	  study	  and	  by	  
January	   1,	   2009	   in	   the	   PREVEND	   study,	   were	   subject	   to	   administrative	   censoring.	   To	   assess	  
reclassification	  we	  calculated	  net	  reclassification	  improvement	  (NRI)	  for	  cardiovascular	  morbidity	  
and	  mortality	  and	  all-­‐cause	  mortality	  (13).	  Given	  the	  difference	  in	  follow-­‐up	  duration	  in	  PREVEND	  
and	  RENAAL,	  we	  calculated	  NRI	  adjusted	  for	  age,	  gender	  as	  well	  as	  for	  duration	  of	  follow-­‐up.	  	  
We	  confirmed	  our	  results	  in	  sensitivity	  analyses.	  First,	  to	  assess	  the	  accuracy	  of	  the	  data,	  an	  
estimated	   UAE	   was	   calculated	   for	   the	   combined	   study	   population	   and	   for	   individual	   studies	  
(calculated	  by	  multiplying	  ACR	  by	  estimated	  creatinine	  excretion	   rate),	   and	   compared	  with	   the	  
actually	   measured	   UAE	   data	   (14).	   Second,	   to	   account	   for	   error	   in	   24-­‐hr	   urine	   collection,	   we	  
excluded	   participants	   with	   possible	   error	   in	   their	   24-­‐hr	   urine	   collection.	   Errors	   in	   24-­‐hr	   urine	  
collection	  were	  assessed	  by	  comparing	  measured	  and	  expected	  24-­‐hr	  urine	  creatinine	  excretion.	  
Participants	   with	   measured	   24hr	   urinary	   creatinine	   excretion	   containing	   less	   than	   50%	   of	   the	  
estimated	   24-­‐hr	   urine	   creatinine	   excretion	   were	   excluded.	   The	   estimated	   creatinine	   excretion	  
rate	  was	  calculated	  according	  to	  literature	  by:	  eCER	  =	  879.89	  +	  12.51	  *	  weight	  (kg)	  -­‐	  6.19	  *	  age	  +	  
(34.51	  if	  black)	  -­‐	  (379.42	  if	  female)	  (15).	  Third,	  given	  the	  difference	  in	  the	  baseline	  characteristics	  
of	  PREVEND	  and	  RENAAL	  study	  participants,	  combining	  cohorts	  might	  confound	  our	  analyses.	  We	  
therefore	   examined	   the	   PREVEND	   and	   RENAAL	   studies	   also	   separately.	   To	   allow	   sufficient	  
numbers	   of	   participants	   in	   three	   albuminuria	   categories,	   in	   both	   PREVEND	   and	   RENAAL,	  
albuminuria	  had	  to	  be	  categorized	  into	  <15,	  15-­‐30	  and	  >30	  (mg/g	  or	  mg/24hr)	  for	  the	  PREVEND	  
study,	  and	  into	  <300,	  300-­‐1500	  and	  >1500	  (mg/g	  or	  mg/24hr)	  for	  the	  RENAAL	  study.	  
All	   calculations	  were	   performed	  with	   STATA	   (version	   12.0)	   software.	   A	   p-­‐value	   of	   less	   than	  





Table	  1	  shows	  the	  baseline	  characteristics	  of	  the	  7,623	  participants.	  Mean	  age	  of	  the	  total	  cohort	  
was	  50.5	  ±	  12.7	  years	  and	  half	  of	  the	  participants	  were	  female.	  When	  albuminuria	  was	  assessed	  
as	  24hr-­‐UAE	  (mg/24h)	  or	  as	  ACR	  (mg/g),	  the	  prevalence	  of	  moderately	  increased	  albuminuria	  was	  
13.5%	  and	  11.5%,	   respectively,	  and	   the	  prevalence	  of	   severely	   increased	  albuminuria	  9.7%	  and	  
8.8%,	   respectively.	   Table	   1	   also	   shows	   that	   when	   participants	   had	   higher	   24hr-­‐UAE	   their	  
cardiovascular	   risk	  profile	  was	  higher,	   i.e.	   these	  participants	  were	  older,	  more	  often	  male,	   had	  
higher	  BMI	  and	  a	  higher	  prevalence	  of	  hypertension	  and	  diabetes.	  
Reclassification	  when	  using	  ACR	  instead	  of	  24hr-­‐UAE	  
When	   using	   ACR	   instead	   of	   24hr-­‐UAE	   88%	   of	   participants	   were	   classified	   in	   corresponding	  
albuminuria	   categories	   (Table	   2).	   307	   (4.0%)	   participants	   were	   classified	   to	   a	   higher	   and	   603	  
(7.9%)	   to	   a	   lower	   category	   (Table	   2).	   Participants	   who	   were	   reclassified	   upward	   to	   a	   higher	  
albuminuria	  category	  when	  using	  ACR	   instead	  of	  24hr-­‐UAE	  (for	  example	  when	  comparing	  24hr-­‐
UAE	  30-­‐300	  mg/24h	  and	  reclassification	  to	  a	  higher	  ACR	  category)	  were	  older	   in	  comparison	  to	  
participants	  that	  were	  not	  reclassified	  (63.8	  ±	  7.4	  vs.	  59.1	  ±	  11.2	  yrs,	  p<0.001),	  and	  more	  often	  of	  
female	   gender	   (64.7	   vs.	   38.3	   %,	   p<0.001),	   diabetic	   (73.5	   vs	   19.5,	   p<0.001)	   and	   hypertensive	  
(97.1%	  vs	  70.0%,	  p<0.001).	  Furthermore,	  they	  had	  a	  higher	  body	  mass	  index	  (29.2	  vs.	  28.2	  kg/m2,	  
p<0.001),	   and	  more	   often	   had	   a	   cardiovascular	   disease	   history	   (42.5%	   vs.	   15.1%,	   p<0.001).	   In	  
contrast,	  the	  participants	  reclassified	  downward	  to	  a	  lower	  albuminuria	  stage	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Table 2 | Characteristics of study participants by urinary albumin categories using the 24hr urinary albumin 
excretion (mg/24hr) and the albumin to creatinine ratio (mg/g) 
 ACR (mg/g)  
 <30  30-300  >300 
UAE (mg/24hr) (n=6,073)  (n=879)  (n=671) 
<30 (n=5,855)      
No. 5,582  266  7 
Age (years) 48.1 ± 12.4  52.4 ± 12.6  50.4 ± 13.7 
Age >65 yrs (%) 644 (11.5)  53 (20.0)  1 (14.3) 
Male (%) 2,667 (47.8)  72 (27.1)  1 (14.3) 
Body mass index (kg/m2) 25.7 ± 3.9  26.6 ± 4.8  23.3 ± 2.8 
Smoking (%) 2,093 (37.7)  88 (33.1)  3 (43.9) 
CVD history (%) 330 (4.9)  16 (6.2)  1 (14.3) 
Diabetes mellitus (%) 129 (2.3)  15 (5.7)  1 (14.3) 
Hypertension (%) 1,618 (29.4)  92 (35.1)  3 (42.9) 
30-300 (n=1,025)      
No. 490  501  34 
Age (years) 53.2 ± 12.4  59.1 ± 11.2  63.8 ± 7.4 
Age >65 yrs (%) 97 (19.8)  187 (36.7)  16 (47.1) 
Male (%) 328 (66.9)  309 (61.7)  12 (35.3) 
Body mass index (kg/m2) 27.7 ± 4.7  28.2 ± 4.6  29.2 ± 6.2 
Smoking (%) 198 (40.6)  189 (37.7)  6 (17.7) 
CVD history (%) 54 (11.3)  67 (15.1)  13 (42.5) 
Diabetes mellitus (%) 45 (9.3)  96 (19.5)  25 (73.5) 
Hypertension (%) 278 (57.4)  348 (70.0)  33 (97.1) 
>300 (n=743)      
No. 1  112  630 
Age (years) NR  59.8 ± 9.3  59.9 ± 8.2 
Age >65 yrs (%) NR  35 (31.3)  179 (28.4) 
Male (%) NR  78 (69.6)  394 (62.5) 
Body mass index (kg/m2) NR  30.5 ± 4.9  29.7 ± 6.3 
Smoking (%) NR  27 (24.3)  118 (18.9) 
CVD history (%) NR  45 (42.3)  465 (75.1) 
Diabetes mellitus (%) NR  75 (68.2)  577 (91.6) 
Hypertension (%) NR  97 (86.6)  600 (95.4) 
Abbreviations are: UAE= urinary albumin excretion, ACR=albumin creatinine concentration, CVD=cardiovascular disease, 
NR=not reliable  
Reclassification and prognosis 
The 7,623 participants had a median follow-up time of 10.7 [7.7 – 11.0] years (a total of 67,652 
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Reclassification and prognosis 
The 7,623 participants had a median follow-up time of 10.7 [7.7 – 11.0] years (a total of 67,652 





of all-cause mortality occurred. Participants that were reclassified upward had higher event rates 
and participants that were reclassified downward had lower event rates when compared to non-
reclassified participants. Cox regression analyses showed that upward reclassification when using 
ACR instead of 24hr-UAE was associated with a significantly increased risk of cardiovascular 
morbidity and all-cause mortality, and all-cause mortality (Table 3). For instance, for 
cardiovascular morbidity and mortality, upward reclassification from 24hr-UAE moderately 
increased albuminuria (30-300 mg/24h) to an ACR severely increased albuminuria (>300 mg/g) 
was associated with a crude Hazard Ratio of 2.67 (95% CI 1.39 – 5.12) and when adjusted for age 
and gender 2.53 (95% CI 1.30 – 4.91). Downward reclassification was associated with a tendency 
to lower risk in crude analyses, but not after adjustment for age and gender (Table 3). Similar 
results were obtained for all-cause mortality. 
Sensitivity analyses 
In the overall study, the median difference in actually measured UAE and the estimated UAE 
(eUAE) was 0.26 [-4.4 – 4.2] mg/24hr and the percentage of individuals with eUAE within 15%, 
20% and 30% of the actually measured UAE were 48% (n=3,650), 64% (n=4,891) and 84% 
(n=6,400), respectively. In the PREVEND study these figures were 0.26 [-4.4 – 4.2] mg/24hr and 
57% (3,941), 70% (n=4,876) and 87% (n=5,999), respectively, whereas in the RENAAL study these 
figures were -56.6 [-528.4 – 187.5] mg/24hr and 43% (n=301), 56% (n=393) and 73% (n=512), 
respectively. The results of analyses after excluding participants with possible errors in their 24-
hr urine collection were essentially similar to the overall results (Appendix Tables 1 - 3). 
Importantly, the results of separately analyzing the PREVEND and RENAAL studies showed similar 
results for the RENAAL and largely the same trend for the PREVEND, although in the latter case 
because off less power some results did not reach formal statistical significance (Appendix Tables 
4-9). 
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When	   using	   the	   NRI	   to	   analyze	   whether	   participants	   were	   reclassified	   upward	   correctly	   to	   a	  
higher	  cardiovascular	  risk	  category	  based	  on	  their	  ACR	  (i.e.	  that	  more	  of	  these	  participants	  had	  a	  
cardiovascular	   event	   during	   follow-­‐up),	   it	   showed	   that	   the	   NRI	   adjusted	   for	   age,	   gender	   and	  
duration	   of	   follow-­‐up	  was	   significantly	   positive	   i.e.	   0.107	   (0.025	  –	   0.189),	   p=0.002.	  NRI	   for	   all-­‐
cause	  mortality	  was	   0.089	   (0.040	  –	   0.138),	   p<0.001.	   Figures	   1	   and	  2	   show	  NRIs	   across	   various	  
subgroups.	  NRIs	  for	  risk	  categorization	  using	  ACR	  instead	  of	  24hr-­‐UAE	  were	  positive	  or	  similar	  in	  
all	  subgroups,	  with	  in	  general	  lower	  values	  obtained	  in	  subgroups	  characterized	  by	  lower	  muscle	  
mass.	  For	  cardiovascular	  events	   the	  NRI	  was	  significantly	   lower	   for	   females	  when	  compared	   to	  
males	  (Figure	  1),	  and	  for	  all-­‐cause	  mortality	  again	  for	  females	  when	  compared	  to	  males,	  as	  well	  
as	  participants	  aged	  upto	  65	  years	  or	  older	  than	  65	  years	  (Figure	  2).	  	  
Figure	  1	  |	  Net	  Reclassification	  Improvements	  (NRIs)	  with	  95%	  confidence	  intervals	  (CI)	  for	  Cardiovascular	  
Morbidity	  and	  Mortality	  for	  various	  subgroups	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Figure 2 | Net Reclassification Improvements (NRIs) with 95% confidence intervals (CI) for All-Cause Mortality 
for various subgroups (*p <0.05 for difference in NRIs) 
 
DISCUSSION 
For practical reasons the ACR has been advocated as the standard method to assess albuminuria 
for chronic kidney disease (CKD) staging instead of 24hr-UAE, which was traditionally regarded to 
be the gold standard to assess albuminuria. This advice has led to concern whether it may lead to 
misclassification and especially overdiagnosis of CKD, because of the creatinine component in the 
ACR, and that upward reclassification by using ACR may not reflect patient characteristics and 
prognosis. We investigated these issues in the present study.  
Various studies have previously compared timed urinary albumin excretion rates (in 24h or 
overnight samples) and ACR, and investigated which ACR values correspond with the traditionally 
used cut-off values for timed urinary albumin excretion rates to define CKD (16, 17). In general 
these studies are difficult to interpret because of the methodological shortcoming that ACR was 
determined in the same urine sample as the timed urinary albumin excretion rate (18). It is 
generally acknowledged that urinary albumin excretion follows a circadian rhythm (19, 20). This 
rhythm is dependent on among others posture, exercise and dietary factors (such as protein and 
fluid intake), with lower values during nighttime than during daytime. It is therefore to be 
expected that the cut-off values of ACR indicating microalbuminuria will be different when these 
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ACR	  should	  be	  measured	  in	  a	  specifically	  collected	  spot	  or	  early	  morning	  void	  urine	  sample	  and	  
compared	   with	   a	   timed	   urinary	   albumin	   excretion	   sample.	   Only	   few	   studies	   followed	   such	   a	  
design,	  but	  these	  studies	  did	  not	   investigate	  what	  the	  consequences	  are	  for	  CKD	  staging	  or	  risk	  
classification	  when	  spot	  ACR	  is	  used	  instead	  of	  timed	  urinary	  albumin	  excretion	  rates	  (21,	  22).	  In	  
an	   earlier	   study	   we	   showed	   that,	   when	   expressed	   continuously,	   ACR	   is	   a	   better	   measure	   of	  
albuminuria	  in	  predicting	  renal	  endpoints	  in	  patients	  with	  type	  2	  diabetes	  and	  nephropathy	  (17).	  
However,	   in	   the	   present	   study,	   using	   classes	   of	   albuminuria,	   we	   provide	   evidence	   on	   the	  
performance	  of	  early	  morning	  void	  ACR	  and	  24hr-­‐UAE	  in	  predicting	  cardiovascular	  events	  and	  all	  
cause	  mortality,	  also	   in	  a	  general	  population	  cohort.	  These	   findings	   relate	   to	   the	   recent	  KDIGO	  
guidelines	  that	  recommend	  for	  clinical	  practice	  albuminuria	  classes	  defined	  using	  early	  morning	  
void	   ACR	   instead	   of	   24hr-­‐UAE.	   The	   findings	   in	   this	   study,	   therefore,	   have	   clear	   clinical	  
implications	  and	  are	  particularly	  important	  for	  clinicians	  in	  assessing	  patient	  prognosis.	  
Our	  findings	  indicate	  that	  using	  ACR	  instead	  of	  24hr-­‐UAE	  does	  not	  lead	  to	  more	  participants	  
being	   labeled	   as	   having	   CKD.	   Only	   a	   limited	   percentage	   of	   participants	   is	   reclassified	   (11.9%),	  
especially	  to	  a	  lower	  albuminuria	  stage	  (7.9%).	  The	  participants	  that	  were	  reclassified	  to	  a	  higher	  
albuminuria	   stage	   (3.9%)	   had	   in	   general	   a	   higher	   cardiovascular	   and	   renal	   risk	   profile,	   and	   an	  
increased	   risk	   for	   cardiovascular	   events	   as	  well	   as	   all-­‐cause	  mortality	  when	   compared	   to	   non-­‐
reclassified	  participants.	  The	  NRI	  when	  using	  ACR	  instead	  of	  24hr-­‐UAE	  for	  risk	  categorization	  was	  
also	  found	  to	  be	  significantly	  positive	  for	  cardiovascular	  events	  as	  well	  as	  for	  all-­‐cause	  mortality.	  
In	  stratified	  analyses	  NRIs	  tended	  to	  be	  lower	  in	  subgroups	  characterized	  by	  lower	  muscle	  mass,	  
but	  were	  positive	  or	  similar	  in	  all	  subgroups.	  	  
Our	   findings	   suggest	   that	  measuring	   albuminuria	   using	   ACR	   instead	   of	   24hr-­‐UAE	   results	   in	  
improved	  reclassification	  with	  respect	  to	  prognosis.	  Improved	  prediction	  of	  prognosis	  using	  ACR	  
might	  be	  because	  of	  improved	  albuminuria	  measurement	  or	  by	  the	  creatinine	  component	  in	  ACR	  
(which	   may	   also	   be	   a	   predictor	   of	   mortality	   (23))	   or	   both.	   We	   found	   that	   in	   participants	  
reclassified	   upward	   from	   the	   24hr-­‐UAE	   albuminuria	   stage	   30-­‐300	   mg/24h	   to	   ACR	   stage	   >300	  
mg/g	   expected	   24hr	   creatinine	   excretion	   was	   1.30	   (0.86	   –	   1.56)	   mg/24	   hr,	   whereas	   actually	  
measured	  creatinine	  excretion	  was	  only	  0.65	  (0.45	  –	  0.80)	  mg/24	  hr	  (p<0.05).	  This	  suggests	  that	  
24hr	   urine	   collection	  may	   have	   been	   incomplete.	   Therefore,	   improved	   prediction	   of	   prognosis	  
using	  ACR	   in	  our	   study	  might	  not	  only	  be	  caused	  by	   the	  creatinine	  component	   in	  ACR,	  but	  can	  
also	  be	  because	  of	  improvement	  in	  albuminuria	  measurement	  by	  correction	  for	  inadequate	  24hr	  
urine	  collection	  that	  is	  inherent	  when	  using	  ACR.	  Furthermore,	  it	  should	  be	  noted	  that	  the	  aim	  of	  
this	   manuscript	   was	   to	   evaluate	   how	   the	   recent	   recommendation	   from	   KDIGO	   about	   staging	  
albuminuria	   in	  classes	  using	  early	  morning	  void	  ACR	   instead	  of	  24hr-­‐UAE	  affects	  prognosis.	  We	  
did	  not	  aim	   to	   investigate	  how	  CKD	   should	  be	  defined	  nor	  what	   the	   causes	   could	  be	  of	  better	  
performance	  of	  ACR	  or	  24hr-­‐UAE	  in	  predicting	  prognosis.	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In our study, the proportion of participants reclassified as having CKD was also lower than the 
proportion of participants reclassified as not having CKD using ACR when cohorts were analyzed 
separately. Therefore, using early morning void ACR instead of 24hr-UAE to stage measure 
albuminuria in clinical practice is therefore likely to lower in clinical practice the number of 
patients to be labelled as having CKD. Because reclassification reflects prognosis correctly, this is 
of clinical relevance. 
It should be noted that to define CKD based on elevated albuminuria should be confirmed 
according to present guidelines. In case of possible incorrect early morning void ACR (e.g. in case 
of sarcopenia) this should be done by a timed albuminuria measurement and in case of possible 
incorrect 24hr-UAE (e.g. in case of considerably less 24hr creatinine excretion than expected) this 
should be done by an early morning void ACR (6). Although fractional albuminuria would be a 
more direct measure of glomerular damage, because it adjusts for serum albumin concentration 
and the number of functioning nephrons, and is not dependent on correctness of 24hr urine 
collections (in contrast to ACR and UAE). Fractional albuminuria, however, has no place in the 
recent KDIGO Guideline for Definition and Classification of CKD, and study and discussion of this 
measure is therefore beyond the scope of the present study. 
We calculated NRI to evaluate ACR against 24hr-UAE for improvement in mortality risk 
stratification. NRI might provide incorrect estimates when studying continuously distributed 
biomarkers or when there are no established thresholds (24). However, compared to other 
methods (e.g. areas under the curve), NRI has been shown to be a reliable method in evaluating 
biomarkers for change in risk stratification when there are already established risk-thresholds 
(25). The number of elderly participants in individual albuminuria categories was limited. This 
might be the reason that the NRI did not reach statistical significance for mortality in elderly. 
However, in this group the NRI was positive both for cardiovascular and all-cause mortality. 
Therefore, we believe that using ACR instead of 24hr-UAE for measuring albuminuria also 
resulted in improved prediction of prognosis in the elderly population. Likewise the lack of a 
statistically significant increase in NRI in female for mortality might be because of the lower 
mortality risk among females than males which results also in limited power. 
This study has limitations that should be acknowledged. First, this analysis comprises 
participants of two separate studies, PREVEND and RENAAL, that differ in design. PREVEND is a 
prospective, observational, general population based cohort study, whereas RENAAL is a double-
blind, randomized, placebo-controlled trial investigating the effect of the angiotensin-2 blocker 
losartan versus placebo in patients with type 2 diabetes and nephropathy. We accounted 
therefore in our Cox regression analyses for differences in design and participant characteristics 
using strata for cohort. In addition, the results of analyzing the PREVEND and RENAAL studies 
separately corroborated our primary findings obtained from combining both studies. Therefore, 
differences in characteristics of PREVEND and RENAAL study participants are unlikely to affect 







ACR	  should	  be	  measured	  in	  a	  specifically	  collected	  spot	  or	  early	  morning	  void	  urine	  sample	  and	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   such	   a	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  not	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  consequences	  are	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  staging	  or	  risk	  
classification	  when	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  rates	  (21,	  22).	  In	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   is	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  nephropathy	  (17).	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  events	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  all	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   findings	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  KDIGO	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  morning	  
void	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   study,	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  well	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   compared	   to	   non-­‐
reclassified	  participants.	  The	  NRI	  when	  using	  ACR	  instead	  of	  24hr-­‐UAE	  for	  risk	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  was	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  NRIs	  tended	  to	  be	  lower	  in	  subgroups	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  by	  lower	  muscle	  mass,	  
but	  were	  positive	  or	  similar	  in	  all	  subgroups.	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  by	  the	  creatinine	  component	  in	  ACR	  
(which	   may	   also	   be	   a	   predictor	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   (0.86	   –	   1.56)	   mg/24	   hr,	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  excretion	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  only	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  (0.45	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  0.80)	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  (p<0.05).	  This	  suggests	  that	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   have	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In our study, the proportion of participants reclassified as having CKD was also lower than the 
proportion of participants reclassified as not having CKD using ACR when cohorts were analyzed 
separately. Therefore, using early morning void ACR instead of 24hr-UAE to stage measure 
albuminuria in clinical practice is therefore likely to lower in clinical practice the number of 
patients to be labelled as having CKD. Because reclassification reflects prognosis correctly, this is 
of clinical relevance. 
It should be noted that to define CKD based on elevated albuminuria should be confirmed 
according to present guidelines. In case of possible incorrect early morning void ACR (e.g. in case 
of sarcopenia) this should be done by a timed albuminuria measurement and in case of possible 
incorrect 24hr-UAE (e.g. in case of considerably less 24hr creatinine excretion than expected) this 
should be done by an early morning void ACR (6). Although fractional albuminuria would be a 
more direct measure of glomerular damage, because it adjusts for serum albumin concentration 
and the number of functioning nephrons, and is not dependent on correctness of 24hr urine 
collections (in contrast to ACR and UAE). Fractional albuminuria, however, has no place in the 
recent KDIGO Guideline for Definition and Classification of CKD, and study and discussion of this 
measure is therefore beyond the scope of the present study. 
We calculated NRI to evaluate ACR against 24hr-UAE for improvement in mortality risk 
stratification. NRI might provide incorrect estimates when studying continuously distributed 
biomarkers or when there are no established thresholds (24). However, compared to other 
methods (e.g. areas under the curve), NRI has been shown to be a reliable method in evaluating 
biomarkers for change in risk stratification when there are already established risk-thresholds 
(25). The number of elderly participants in individual albuminuria categories was limited. This 
might be the reason that the NRI did not reach statistical significance for mortality in elderly. 
However, in this group the NRI was positive both for cardiovascular and all-cause mortality. 
Therefore, we believe that using ACR instead of 24hr-UAE for measuring albuminuria also 
resulted in improved prediction of prognosis in the elderly population. Likewise the lack of a 
statistically significant increase in NRI in female for mortality might be because of the lower 
mortality risk among females than males which results also in limited power. 
This study has limitations that should be acknowledged. First, this analysis comprises 
participants of two separate studies, PREVEND and RENAAL, that differ in design. PREVEND is a 
prospective, observational, general population based cohort study, whereas RENAAL is a double-
blind, randomized, placebo-controlled trial investigating the effect of the angiotensin-2 blocker 
losartan versus placebo in patients with type 2 diabetes and nephropathy. We accounted 
therefore in our Cox regression analyses for differences in design and participant characteristics 
using strata for cohort. In addition, the results of analyzing the PREVEND and RENAAL studies 
separately corroborated our primary findings obtained from combining both studies. Therefore, 





our findings. Second, despite the combination of the two studies, still some cells in the cross-
tabulation tables included a relatively low number of participants, which consequently leads to 
limited power when analyzing differences between non-recategorized and recategorized 
participants. Third, we used for our analyses early morning void urine samples, whereas in clinical 
practice often spot urine samples are used. It has been suggested that early morning void urine 
samples may be more reliable than a spot urine sample to diagnose and monitor increased 
albuminuria (13). Whether our results will be similar when using spot urine samples instead of 
early morning voids needs therefore additional study.  
Strengths of this study are the availability of a large number of participants with higher levels 
of albuminuria, and that in participants both 24hr-UAE as well as ACR in an early morning void 
were assessed. Only very few other epidemiological studies, if any, collected these data 
simultaneously. Furthermore, albuminuria was measured in fresh urine samples like in clinical 
practice, and not in samples that have been stored frozen. It has previously been shown that 
frozen storage of urine samples leads to a decrease in average urinary albumin concentration, 
with more variability, which negatively affects the prognostic value of albuminuria (27). 
Furthermore, in study participants data on incident cardiovascular events and mortality were 
collected prospectively. Lastly, by design we excluded subjects in whom it was likely that 24h 
urine collection was inadequate. Even in this scenario using ACR was as strong, or even stronger, 
for risk categorization when compared to using 24hr-UAE, which makes our findings robust. 
In conclusion, our results indicate that reclassification when using ACR instead of 24hr-UAE is 
limited, that reclassification is more often downward than upward, leading to a smaller number 
of subjects being labelled as having CKD, and that upward reclassified subjects have a worse 
prognosis with respect to incident cardiovascular events and mortality and downward reclassified 
subjects have a lower risk. These data thus do not provide evidence for overdiagnosis of CKD or 
to misclassification with respect to prognosis in reclassified subjects when using ACR instead of 
24hr-UAE. Consequently our findings support the advice of the prevailing KDIGO guidelines to use 
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participants. Third, we used for our analyses early morning void urine samples, whereas in clinical 
practice often spot urine samples are used. It has been suggested that early morning void urine 
samples may be more reliable than a spot urine sample to diagnose and monitor increased 
albuminuria (13). Whether our results will be similar when using spot urine samples instead of 
early morning voids needs therefore additional study.  
Strengths of this study are the availability of a large number of participants with higher levels 
of albuminuria, and that in participants both 24hr-UAE as well as ACR in an early morning void 
were assessed. Only very few other epidemiological studies, if any, collected these data 
simultaneously. Furthermore, albuminuria was measured in fresh urine samples like in clinical 
practice, and not in samples that have been stored frozen. It has previously been shown that 
frozen storage of urine samples leads to a decrease in average urinary albumin concentration, 
with more variability, which negatively affects the prognostic value of albuminuria (27). 
Furthermore, in study participants data on incident cardiovascular events and mortality were 
collected prospectively. Lastly, by design we excluded subjects in whom it was likely that 24h 
urine collection was inadequate. Even in this scenario using ACR was as strong, or even stronger, 
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of subjects being labelled as having CKD, and that upward reclassified subjects have a worse 
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